|
|
|
|
||
Re: ImmunoGen and Merck Establish Collaboration"A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab (NCT02318901)" Yes Sooner, this trial pretty much unchanged, has been ongoing for circa a year and positive results from the MBC Keytruda/Kadcyla arm might have been instrumental in looking at this agent with IMGN853. https://www.clinicaltrials.gov/ct2/show/NCT02318901?term=NCT02318901&rank=1 |
return to message board, top of board |